anti-cd30/cd3 bispecific antibody gen3017
Generic: Anti-CD30/CD3 Bispecific Antibody GEN3017
anti-cd30/cd3 bispecific antibody gen3017: 1 clinical trial tracked.
anti-cd30/cd3 bispecific antibody gen3017 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-cd30/cd3 bispecific antibody gen3017, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
Primary endpoint: Dose Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs)
Interventionalopen9 targetStarted 2023-09Completion 2025-024 sites · Australia, United StatesGenmab